A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

TNKase will be available for the treatment of acute ischemic stroke in adults, joining the Roche subsidiary’s Activase (alteplase) on the market – also approved for the same indication.

The 5-second intravenous bolus offers faster, simpler administration than Activase. (HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or ...

TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed ...

The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults. TNKase is delivered as a ...

The US Food and Drug Administration (FDA) has approved the thrombolytic tenecteplase (TNKase, Genentech) for treatment of acute ischemic stroke in adults. The drug is administered as a single, 5 ...

Summary. Stroke is the leading cause of disability in the elderly, and i.v. alteplase (recombinant tissue plasminogen activator) is the only Food and Drug Administration (FDA)-approved ...

TNKase is delivered as a single five-second intravenous (IV) bolus, a faster and simpler administration compared to the standard-of-care, Activase, which is administered as an IV bolus followed by ...

unlike Activase (alteplase), which requires an IV injection followed by a 60-minute drip. The FDA approval was based on a large study conducted by the University of Calgary across 22 stroke ...